Upadacitinib

• JAK inhibitor that targets JAK1
• Indications include rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, Crohn disease, and ulcerative colitis
• Adverse effects include: upper respiratory tract infection, nausea, hepatotoxicity
• Reports of lymphopenia, neutropenia, and anemia